vimarsana.com
Home
Live Updates
Tr1X Announces FDA Clearance of First Investigational New Drug Application for TRX103, an Allogeneic Regulatory T-Cell Therapy to Treat Autoimmune Diseases : comparemela.com
Tr1X Announces FDA Clearance of First Investigational New Drug Application for TRX103, an Allogeneic Regulatory T-Cell Therapy to Treat Autoimmune Diseases
/PRNewswire/ -- Tr1X, Inc., an autoimmune and inflammatory disease cell therapy company focused on the development of novel allogeneic regulatory T cell...
Related Keywords
California ,
United States ,
Alexandria ,
Al Iskandariyah ,
Egypt ,
Monzrm Al Malki ,
Maria Grazia Roncarolo ,
Drug Administration ,
X Inc ,
Column Group ,
California Institute For Regenerative Medicine ,
Department Of Hematology Hematopoietic Cell Transplantation ,
Host Disease ,
Chimeric Antigen Receptors ,
Investigational New Drug ,
Associate Professor ,
Hematopoietic Cell Transplantation ,
Unrelated Donor ,
Cord Blood Transplant Programs ,
Hope National Medical ,
Alexandria Venture Investments ,
California Institute ,
Regenerative Medicine ,
comparemela.com © 2020. All Rights Reserved.